OBJECTIVE: Central nervous system (CNS) involvement occurs frequently in systemic lupus erythematosus (SLE) and frequently results in morbidity. The primary pathophysiology of CNS involvement in SLE is thought to be inflammation secondary to autoantibody-mediated vasculitis. Neuroimaging studies have shown hypometabolism (representing impending cell failure) and atrophy (representing late-stage pathology), but not inflammation. The purpose of this study was to detect the presence and regional distribution of inflammation (hypermetabolism) and tissue failure, apoptosis, or atrophy (hypometabolism). METHODS: Eighty-five patients with newly diagnosed SLE, who had no focal neurologic symptoms, were studied. Disease activity was quantified using the Safety of Estrogens in Lupus Erythematosus: National Assessment version of the SLE Disease Activity Index (SELENA-SLEDAI), a validated index of SLE-related disease activity. 18Fluorodeoxyglucose (FDG) positron emission tomography (PET) images of glucose uptake were analyzed by visual inspection and as group statistical parametric images, using the SELENA-SLEDAI score as the analysis regressor. RESULTS: SELENA-SLEDAI-correlated increases in glucose uptake were found throughout the white matter, most markedly in heavily myelinated tracts. SELENA-SLEDAI-correlated decreases were found in the frontal and parietal cortex, in a pattern similar to that seen during visual inspection and presented in previous reports of hypometabolism. CONCLUSION: The SELENA-SLEDAI-correlated increases in glucose consumption are potential evidence of inflammation, consistent with prior reports of hypermetabolism in inflammatory disorders. To our knowledge, this is the first imaging-based evidence of SLE-induced CNS inflammation in an SLE inception cohort. The dissociation among 18FDG uptake characteristics, spatial distribution, and disease activity correlation is in accordance with the notion that glucose hypermetabolism and hypometabolism reflect fundamentally different aspects of the pathophysiology of SLE with CNS involvement.
OBJECTIVE: Central nervous system (CNS) involvement occurs frequently in systemic lupus erythematosus (SLE) and frequently results in morbidity. The primary pathophysiology of CNS involvement in SLE is thought to be inflammation secondary to autoantibody-mediated vasculitis. Neuroimaging studies have shown hypometabolism (representing impending cell failure) and atrophy (representing late-stage pathology), but not inflammation. The purpose of this study was to detect the presence and regional distribution of inflammation (hypermetabolism) and tissue failure, apoptosis, or atrophy (hypometabolism). METHODS: Eighty-five patients with newly diagnosed SLE, who had no focal neurologic symptoms, were studied. Disease activity was quantified using the Safety of Estrogens in Lupus Erythematosus: National Assessment version of the SLE Disease Activity Index (SELENA-SLEDAI), a validated index of SLE-related disease activity. 18Fluorodeoxyglucose (FDG) positron emission tomography (PET) images of glucose uptake were analyzed by visual inspection and as group statistical parametric images, using the SELENA-SLEDAI score as the analysis regressor. RESULTS: SELENA-SLEDAI-correlated increases in glucose uptake were found throughout the white matter, most markedly in heavily myelinated tracts. SELENA-SLEDAI-correlated decreases were found in the frontal and parietal cortex, in a pattern similar to that seen during visual inspection and presented in previous reports of hypometabolism. CONCLUSION: The SELENA-SLEDAI-correlated increases in glucose consumption are potential evidence of inflammation, consistent with prior reports of hypermetabolism in inflammatory disorders. To our knowledge, this is the first imaging-based evidence of SLE-induced CNS inflammation in an SLE inception cohort. The dissociation among 18FDG uptake characteristics, spatial distribution, and disease activity correlation is in accordance with the notion that glucose hypermetabolism and hypometabolism reflect fundamentally different aspects of the pathophysiology of SLE with CNS involvement.
Authors: Yawu Liu; Jari O Karonen; Juho Nuutinen; Esko Vanninen; Jyrki T Kuikka; Ritva L Vanninen Journal: J Cereb Blood Flow Metab Date: 2007-02-21 Impact factor: 6.200
Authors: Charles G Helmick; David T Felson; Reva C Lawrence; Sherine Gabriel; Rosemarie Hirsch; C Kent Kwoh; Matthew H Liang; Hilal Maradit Kremers; Maureen D Mayes; Peter A Merkel; Stanley R Pillemer; John D Reveille; John H Stone Journal: Arthritis Rheum Date: 2008-01
Authors: L Podrazilová; V Peterová; M Olejárová; D Tegzová; J Krásenský; Z Seidl; P Kozelek; C Dostál Journal: Clin Exp Rheumatol Date: 2008 Jul-Aug Impact factor: 4.473
Authors: Michelle Petri; Mohammad Naqibuddin; Kathryn A Carson; Daniel J Wallace; Michael H Weisman; Stephen L Holliday; Margaret Sampedro; Shalini Narayana; Peter T Fox; Crystal Franklin; Patricia A Padilla; Robin L Brey Journal: J Rheumatol Date: 2008-09-15 Impact factor: 4.666
Authors: H Fragoso-Loyo; Y Richaud-Patin; A Orozco-Narváez; L Dávila-Maldonado; Y Atisha-Fregoso; L Llorente; J Sánchez-Guerrero Journal: Arthritis Rheum Date: 2007-04
Authors: Tapan K Mondal; Sam K Saha; Veronica M Miller; Richard F Seegal; David A Lawrence Journal: Brain Behav Immun Date: 2008-04-14 Impact factor: 7.217
Authors: Catherine B Driver; Daniel J Wallace; Jessica C Lee; Chelsey J Forbess; Shahram Pourrabbani; Satoshi Minoshima; Alan D Waxman; Michael H Weisman Journal: Arthritis Rheum Date: 2008-03-15
Authors: B Cesar; M G Dwyer; J L Shucard; P Polak; N Bergsland; R H B Benedict; B Weinstock-Guttman; D W Shucard; R Zivadinov Journal: AJNR Am J Neuroradiol Date: 2015-06-11 Impact factor: 3.825
Authors: Yuchuan Wang; Jennifer M Coughlin; Shuangchao Ma; Christopher J Endres; Michael Kassiou; Akira Sawa; Robert F Dannals; Michelle Petri; Martin G Pomper Journal: Lupus Date: 2016-07-11 Impact factor: 2.911